Virax Biolabs Group Limited

NasdaqCM:VRAX Stock Report

Market Cap: US$7.3m

Virax Biolabs Group Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

James Foster

Chief executive officer

US$650.8k

Total compensation

CEO salary percentage49.9%
CEO tenure2.8yrs
CEO ownership6.6%
Management average tenure2.1yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Virax stock soars 40% on launch of monkeypox rapid test kits

Sep 20

Virax Biolabs soars 37% on launch of real-time PCR test for monkeypox in Europe

Jul 26

CEO Compensation Analysis

How has James Foster's remuneration changed compared to Virax Biolabs Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$7m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024US$651kUS$325k

-US$7m

Dec 31 2023n/an/a

-US$7m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023US$2mUS$248k

-US$5m

Dec 31 2022n/an/a

-US$4m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022US$138kUS$138k

-US$2m

Dec 31 2021n/an/a

-US$1m

Sep 30 2021n/an/a

-US$860k

Jun 30 2021n/an/a

-US$755k

Mar 31 2021US$267kn/a

-US$651k

Compensation vs Market: James's total compensation ($USD650.80K) is about average for companies of similar size in the US market ($USD640.24K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James Foster (39 yo)

2.8yrs

Tenure

US$650,800

Compensation

Mr. James Foster is co-founder of Virax Biolabs Group Limited and has been its Chief Executive Officer and serves as its Director & Chairman since May 2022. From 2014 to July 2018, Mr. Foster co-founded an...

Leadership Team

NamePositionTenureCompensationOwnership
James Foster
Chairman & CEOno dataUS$650.80k6.63%
$ 486.7k
Jason Davis
Chief Financial Officer2.8yrsUS$625.12kno data
Nigel McCracken
COO & Chief Technical Officer1.4yrsUS$425.09kno data
Joel Yeung
Accounting Manager2.1yrsno datano data
Clement Monteil
Head of Scientific Research & Development2.2yrsno datano data
Lily Fu
Head of Supply Chainno datano datano data

2.1yrs

Average Tenure

52yo

Average Age

Experienced Management: VRAX's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Foster
Chairman & CEO2.8yrsUS$650.80k6.63%
$ 486.7k
Nikolas Perrault
Member of Advisory Board3.6yrsno datano data
Karen Bertoli
Member of Advisory Board3.3yrsno datano data
Evan Norton
Independent Director2.8yrsUS$100.30kno data
Nelson Haight
Independent Director2.3yrsUS$100.30kno data
Cameron Shaw
Member of Advisory Board2.1yrsUS$243.46kno data
Yair Erez
Independent Director2.8yrsUS$100.30kno data
Bruce Lavin
Member of Advisory Board3.3yrsno datano data
Pierre Frouin
Member of Advisory Board3.2yrsno datano data
Asaf Gol
Member of Advisory Board3.3yrsno datano data
Ian Hampson
Member of Advisory Board3.4yrsno datano data
Marc Frouin
Member of Advisory Board3.3yrsno datano data

3.2yrs

Average Tenure

49yo

Average Age

Experienced Board: VRAX's board of directors are considered experienced (3.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 08:49
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Virax Biolabs Group Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas KerrZacks Small-Cap Research